Login Register Cart 0
Generic placeholder image

Current Medical Imaging

Editor-in-Chief

ISSN (Print): 1573-4056
ISSN (Online): 1875-6603

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Current MRI Methods for the Assessment of Pathologic Prostate: A Brief Review for Clinicians

Author(s): Shirley-Yoselin Salazar-Ruiz, Maria-Fatima Chilaca-Rosas, Irma-Gabriela Sanchez-Rodriguez, Roberto Corona-Cedillo, Sergey K. Ternovoy and Ernesto Roldan-Valadez*

Volume 18, Issue 8, 2022

Published on: 17 March, 2022

Article ID: e171221199110 Pages: 9

DOI: 10.2174/1573405618666211217101542

Price: $65

conference banner
Abstract

The application of Magnetic Resonance Imaging (MRI) have helped in different modalities for prostate cancer management, from early detection to treatment planning and follow-up, the evolution of MRI techniques allows to obtain not only anatomical but also functional information to take advantage of prostate cancer detection and staging while supplying prognostic and predictive biomarkers. This review presents conventional and advanced MRI techniques (known as multiparametric MRI) that allow functional and quantitative assessment of the normal prostate gland and its correlation with prostate cancer. Additional topics include the epidemiology of prostate cancer following the Global Burden Diseases Cancer Collaboration 2018, the clinical anatomy of the prostate gland, and the lower urinary tract; we also mention some aspects of the diagnosis performance in ultrasound. We end the review with a brief explanation about the anatomical foundation of external-beam planning radiotherapy.

Keywords: Diffusion, magnetic resonance imaging, contrast media, magnetic resonance spectroscopy, perfusion imaging, prostatic neoplasms.

Graphical Abstract

[1]
Fitzmaurice C, Akinyemiju TF, Al Lami FH, et al. Global Burden of Disease Cancer Collaboration. Global Burden of Disease Cancer C. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2016: A systematic analysis for the global burden of disease study. JAMA Oncol 2018; 4(11): 1553-68.
[http://dx.doi.org/10.1001/jamaoncol.2018.2706] [PMID: 29860482]
[2]
Li L, Wang L, Feng Z, et al. Prostate cancer Magnetic Resonance Imaging (MRI): multidisciplinary standpoint. Quant Imaging Med Surg 2013; 3(2): 100-12.
[PMID: 23630657]
[3]
Mazaheri Y, Shukla-Dave A, Muellner A, Hricak H. MRI of the prostate: Clinical relevance and emerging applications. J Magn Reson Imaging 2011; 33(2): 258-74.
[http://dx.doi.org/10.1002/jmri.22420] [PMID: 21274967]
[4]
Pernar CH, Ebot EM, Wilson KM, Mucci LA. The epidemiology of prostate cancer. Cold Spring Harb Perspect Med 2018; 8(12): a030361.
[http://dx.doi.org/10.1101/cshperspect.a030361] [PMID: 29311132]
[5]
Yacoub JH, Oto A. MR imaging of prostate zonal anatomy. Radiol Clin North Am 2018; 56(2): 197-209.
[http://dx.doi.org/10.1016/j.rcl.2017.10.003] [PMID: 29420976]
[6]
McNeal JE. Anatomy of the prostate and morphogenesis of BPH. Prog Clin Biol Res 1984; 145: 27-53.
[PMID: 6201879]
[7]
Aaron L, Franco OE, Hayward SW. Review of prostate anatomy and embryology and the etiology of benign prostatic hyperplasia. Urol Clin North Am 2016; 43(3): 279-88.
[http://dx.doi.org/10.1016/j.ucl.2016.04.012] [PMID: 27476121]
[8]
Bathle JC, Busquets JC, Obregón JB, et al. The diagnosis of prostate cancer by endorectal MR spectroscopy. Arch Esp Urol 2006; 59(10): 953-63.
[PMID: 17283709]
[9]
Mitterberger M, Horninger W, Aigner F, et al. Ultrasound of the prostate. Cancer Imaging 2010; 10(1): 40-8.
[http://dx.doi.org/10.1102/1470-7330.2010.0004] [PMID: 20199941]
[10]
Afnan J, Tempany CM. Update on prostate imaging. Urol Clin North Am 2010; 37(1): 23-5.
[http://dx.doi.org/10.1016/j.ucl.2009.11.009] [PMID: 20152516]
[11]
Mitterberger M, Pelzer A, Colleselli D, et al. Contrast-enhanced ultrasound for diagnosis of prostate cancer and kidney lesions. Eur J Radiol 2007; 64(2): 231-8.
[http://dx.doi.org/10.1016/j.ejrad.2007.07.027] [PMID: 17881175]
[12]
Ismail M, Gomella LG. Ultrasound for prostate imaging and biopsy. Curr Opin Urol 2001; 11(5): 471-7.
[http://dx.doi.org/10.1097/00042307-200109000-00004] [PMID: 11493767]
[13]
Bonekamp D, Jacobs MA, El-Khouli R, Stoianovici D, Macura KJ. Advancements in MR imaging of the prostate: From diagnosis to interventions. Radiographics 2011; 31(3): 677-703.
[http://dx.doi.org/10.1148/rg.313105139] [PMID: 21571651]
[14]
Lorentzen T, Nerstrom H, Torp-Pedersen ST, Iversen P. Local staging of prostate cancer with transrectal ultrasound: A literature review. 1992; 21(S4): 11-6.
[http://dx.doi.org/10.1002/pros.2990210504]
[15]
Steinkohl F, Luger A, Bektic J, Aigner F. Ultrasonography of the prostate gland: From B-image through multiparametric ultrasound to targeted biopsy. Radiologe 2017; 57(8): 615-20.
[http://dx.doi.org/10.1007/s00117-017-0274-3] [PMID: 28702693]
[16]
Spajic B, Eupic H, Tomas D, Stimac G, Kruslin B, Kraus O. The incidence of hyperechoic prostate cancer in transrectal ultrasound-guided biopsy specimens. Urology 2007; 70(4): 734-7.
[http://dx.doi.org/10.1016/j.urology.2007.06.1092] [PMID: 17991546]
[17]
Laguna MP, Wondergem N, Wink MH, Wijkstra H, de la Rosette J. Advances in the ultrasound diagnosis of prostate cancer. Arch Esp Urol 2006; 59(10): 965-76.
[PMID: 17283710]
[18]
Sigrist RMS, Liau J, Kaffas AE, Chammas MC, Willmann JK. Ultrasound elastography: Review of techniques and clinical applications. Theranostics 2017; 7(5): 1303-29.
[http://dx.doi.org/10.7150/thno.18650] [PMID: 28435467]
[19]
Thickman D, Miller GJ, Hopper KD, Raife M. Prostate cancer: comparison of pre-operative 0.35 T MRI with whole-mount histopathology. Magn Reson Imaging 1990; 8(3): 205-11.
[http://dx.doi.org/10.1016/0730-725X(90)90090-O] [PMID: 1694949]
[20]
Roethke MC, Kuru TH, Schultze S, et al. Evaluation of the ESUR PI-RADS scoring system for multiparametric MRI of the prostate with targeted MR/TRUS fusion-guided biopsy at 3.0 Tesla. Eur Radiol 2014; 24(2): 344-52.
[http://dx.doi.org/10.1007/s00330-013-3017-5] [PMID: 24196383]
[21]
Purysko AS, Rosenkrantz AB. Technique of multiparametric MR imaging of the prostate. Urol Clin North Am 2018; 45(3): 427-38.
[http://dx.doi.org/10.1016/j.ucl.2018.03.008] [PMID: 30031463]
[22]
Dickinson L, Ahmed HU, Allen C, et al. Magnetic resonance imaging for the detection, localisation, and characterisation of prostate cancer: Recommendations from a European consensus meeting. Eur Urol 2011; 59(4): 477-94.
[http://dx.doi.org/10.1016/j.eururo.2010.12.009] [PMID: 21195536]
[23]
Paganini L, Ocantos J, A, Pietrani M. Resonancia magnética de próstata: Morfología y metabolismo 2007.
[24]
Ma C, Chen L, Scheenen TWJ, Lu J, Wang J. Three-dimensional proton magnetic resonance spectroscopic imaging with and without an endorectal coil: A prostate phantom study. Acta Radiol 2015; 56(11): 1342-9.
[http://dx.doi.org/10.1177/0284185114556704] [PMID: 25348479]
[25]
Turkbey B, Pinto PA, Mani H, et al. Prostate cancer: Value of multiparametric MR imaging at 3 T for detection-histopathologic correlation. Radiology 2010; 255(1): 89-99.
[http://dx.doi.org/10.1148/radiol.09090475] [PMID: 20308447]
[26]
Claus FG, Hricak H, Hattery RR. Pretreatment evaluation of prostate cancer: Role of MR imaging and 1H MR spectroscopy. Radiographics 2004; 24(Suppl. 1): S167-80.
[http://dx.doi.org/10.1148/24si045516] [PMID: 15486239]
[27]
Li H, Sugimura K, Kaji Y, et al. Conventional MRI capabilities in the diagnosis of prostate cancer in the transition zone. AJR Am J Roentgenol 2006; 186(3): 729-42.
[http://dx.doi.org/10.2214/AJR.04.0775] [PMID: 16498100]
[28]
Coakley FV, Hricak H. Radiologic anatomy of the prostate gland: A clinical approach. Radiol Clin North Am 2000; 38(1): 15-30.
[http://dx.doi.org/10.1016/S0033-8389(05)70147-0] [PMID: 10664664]
[29]
Kwon T, Kim JK, Lee C, et al. Discrimination of local recurrence after radical prostatectomy: Value of diffusion-weighted magnetic resonance imaging. Prostate Int 2018; 6(1): 12-7.
[http://dx.doi.org/10.1016/j.prnil.2017.05.002] [PMID: 29556484]
[30]
M. V. Imaging methods in prostate cancer In: Prostate Cancer. Buenos Aires, Argentina: Editorial Mexicana Panamericana 2014; pp. 39-55.
[31]
Wu X, Reinikainen P, Kapanen M, Vierikko T, Ryymin P, Kellokumpu-Lehtinen PL. Dynamic contrast-enhanced imaging as a prognostic tool in early diagnosis of prostate cancer: Correlation with PSA and clinical stage. Contrast Media Mol Imaging 2018; 2018: 3181258.
[http://dx.doi.org/10.1155/2018/3181258] [PMID: 30327584]
[32]
De Visschere P, Lumen N, Ost P, Decaestecker K, Pattyn E, Villeirs G. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA. Clin Radiol 2017; 72(1): 23-32.
[http://dx.doi.org/10.1016/j.crad.2016.09.011] [PMID: 27726850]
[33]
Barentsz JO, Richenberg J, Clements R, et al. European Society of Urogenital Radiology. ESUR prostate MR guidelines 2012. Eur Radiol 2012; 22(4): 746-57.
[http://dx.doi.org/10.1007/s00330-011-2377-y] [PMID: 22322308]
[34]
Alonzi R, Padhani AR, Allen C. Dynamic contrast enhanced MRI in prostate cancer. Eur J Radiol 2007; 63(3): 335-50.
[http://dx.doi.org/10.1016/j.ejrad.2007.06.028] [PMID: 17689907]
[35]
Katelaris NC, Bolton DM, Weerakoon M, Toner L, Katelaris PM, Lawrentschuk N. Current role of multiparametric magnetic resonance imaging in the management of prostate cancer. Korean J Urol 2015; 56(5): 337-45.
[http://dx.doi.org/10.4111/kju.2015.56.5.337] [PMID: 25964833]
[36]
Kurhanewicz J, Vigneron DB, Males RG, Swanson MG, Yu KK, Hricak H. The prostate: MR imaging and spectroscopy. Present and future. Radiol Clin North Am 2000; 38(1): 115-138, viii-ix.
[http://dx.doi.org/10.1016/S0033-8389(05)70152-4] [PMID: 10664669]
[37]
Euceda LR, Andersen MK, Tessem MB, Moestue SA, Grinde MT, Bathen TF. NMR-based prostate cancer metabolomics. Methods Mol Biol 2018; 1786: 237-57.
[http://dx.doi.org/10.1007/978-1-4939-7845-8_14] [PMID: 29786797]
[38]
Kurhanewicz J, Vigneron DB, Hricak H, Narayan P, Carroll P, Nelson SJ. Three-dimensional H-1 MR spectroscopic imaging of the in situ human prostate with high (0.24-0.7-cm3) spatial resolution. Radiology 1996; 198(3): 795-805.
[http://dx.doi.org/10.1148/radiology.198.3.8628874] [PMID: 8628874]
[39]
Kirlik G, Gullapalli R, D’Souza W, et al. A supervised learning tool for prostate cancer foci detection and aggressiveness identification using multiparametric magnetic resonance imaging/magnetic resonance spectroscopy imaging. Cancer Inform 2018; 17: 1176935118786260.
[http://dx.doi.org/10.1177/1176935118786260] [PMID: 30013306]
[40]
Yacoub JH, Oto A, Miller FH. MR imaging of the prostate. Radiol Clin North Am 2014; 52(4): 811-37.
[http://dx.doi.org/10.1016/j.rcl.2014.02.010] [PMID: 24889173]
[41]
Verma S, Rajesh A, Fütterer JJ, et al. Prostate MRI and 3D MR spectroscopy: How we do it. AJR Am J Roentgenol 2010; 194(6): 1414-26.
[http://dx.doi.org/10.2214/AJR.10.4312] [PMID: 20489079]
[42]
Das B, Shoukat S, Bux KI, Mahmood T, Nisar H, Raheem A. Correlation between MR spectroscopy and histology in detection of prostatic carcinoma. J Pak Med Assoc 2018; 68(7): 986-9.
[PMID: 30317288]
[43]
Weinreb JC, Barentsz JO, Choyke PL, et al. PI-RADS Prostate Imaging - Reporting and Data System: 2015, version 2. Eur Urol 2016; 69(1): 16-40.
[http://dx.doi.org/10.1016/j.eururo.2015.08.052] [PMID: 26427566]
[44]
Bruner DW, Hunt D, Michalski JM, et al. Preliminary patient-reported outcomes analysis of 3-dimensional radiation therapy versus intensity-modulated radiation therapy on the high-dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial. Cancer 2015; 121(14): 2422-30.
[http://dx.doi.org/10.1002/cncr.29362] [PMID: 25847819]
[45]
Michalski JM, Moughan J, Purdy J, et al. Effect of standard vs. dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: The NRG Oncology RTOG 0126 randomized clinical trial. JAMA Oncol 2018; 4(6): e180039.
[http://dx.doi.org/10.1001/jamaoncol.2018.0039] [PMID: 29543933]
[46]
Potrebko PS, McCurdy BM, Butler JB, El-Gubtan AS, Nugent Z. Optimal starting gantry angles using equiangular-spaced beams with intensity modulated radiation therapy for prostate cancer on RTOG 0126: A clinical study of 5 and 7 fields. Radiother Oncol 2007; 85(2): 299-305.
[http://dx.doi.org/10.1016/j.radonc.2007.06.019] [PMID: 17825932]
[47]
Parker CC, Damyanovich A, Haycocks T, Haider M, Bayley A, Catton CN. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 2003; 66(2): 217-24.
[http://dx.doi.org/10.1016/S0167-8140(02)00407-3] [PMID: 12648794]
[48]
Usmani N, Sloboda R, Kamal W, et al. Can images obtained with high field strength magnetic resonance imaging reduce contouring variability of the prostate? Int J Radiat Oncol Biol Phys 2011; 80(3): 728-34.
[http://dx.doi.org/10.1016/j.ijrobp.2010.03.019] [PMID: 20630667]
[49]
Henderson DR, Tree AC, Harrington KJ, van As NJ. Dosimetric implications of computerised tomography-only versus magnetic resonance-fusion contouring in stereotactic body radiotherapy for prostate cancer. Medicines (Basel) 2018; 5(2): E32.
[http://dx.doi.org/10.3390/medicines5020032] [PMID: 29621134]
[50]
Morrison K, Tree A, Khoo V, As NJV, TMG OBotP. The PACE trial: International randomised study of laparoscopic prostatectomy vs. Stereotactic Body Radiotherapy (SBRT) and standard radiotherapy vs. SBRT for early stage organ-confined prostate cancer. 2018; 36(6_suppl): TPS153-53.
[51]
Oliai C, Lanciano R, Sprandio B, et al. Stereotactic body radiation therapy for the primary treatment of localized prostate cancer. J Radiat Oncol 2013; 2(1): 63-70.
[http://dx.doi.org/10.1007/s13566-012-0067-2] [PMID: 23504305]
[52]
Henderson DR, Tree AC, van As NJ. Stereotactic body radiotherapy for prostate cancer. Clin Oncol (R Coll Radiol) 2015; 27(5): 270-9.
[http://dx.doi.org/10.1016/j.clon.2015.01.011] [PMID: 25707911]
[53]
Xu H, Zhu Y, Dai B, Ye DW. National Comprehensive Cancer Network (NCCN) risk classification in predicting biochemical recurrence after radical prostatectomy: A retrospective cohort study in Chinese prostate cancer patients. Asian J Androl 2018; 20(6): 551-4.
[http://dx.doi.org/10.4103/aja.aja_52_18] [PMID: 30027928]
[54]
NCCN Clinical Practice Guidelines in Oncology Prostate Cancer Version 2. Available from:https://www.nccn.org/professionals/physician_gls/pdf/prostate_blocks.pdf
[55]
Benedict SH, Yenice KM, Followill D, et al. Stereotactic body radiation therapy: the report of AAPM Task Group 101. Med Phys 2010; 37(8): 4078-101.
[http://dx.doi.org/10.1118/1.3438081] [PMID: 20879569]
[56]
Ng IWS, Tey JCS, Soon YY, Tseng MSF, Chen D, Lim KHC. Outcomes of Asian patients with localised prostate cancer treated with combined intensity modulated radiation therapy (IMRT) and high dose rate (HDR) brachytherapy: A single institution experience. Asia Pac J Clin Oncol 2018; 14(5): e386-91.

Rights & Permissions Print Cite
Article Metrics
33
1
Wayfinder Image
© 2024 Bentham Science Publishers | Privacy Policy